Journal for immunotherapy of cancer
Journal
Overview
publication venue for
-
Circulating tumor DNA (ctDNA) serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer.
2022
-
Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series.
2019
-
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
2018
-
Trial Reporting in Immuno-Oncology (TRIO): an American society of clinical oncology-society for immunotherapy of cancer statement.
2018
-
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy.
2018
-
Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.
2018
-
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
2018
-
Cytokine release syndrome after radiation therapy: case report and review of the literature.
2018
-
Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone.
2017
-
Immunotherapy-associated autoimmune hemolytic anemia.
2017
-
Nivolumab induced myxedema crisis.
2017
-
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
2017
-
Management of immune-related cutaneous adverse events with dupilumab..
11.
2023
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer..
11.
2023
-
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors..
11.
2023
-
TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma..
11.
2023
-
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors..
11.
2023
-
Trojan-horse silk fibroin nanocarriers loaded with a re-call antigen to redirect immunity against cancer..
11.
2023
-
Ensuring equity in the era of HLA-restricted cancer therapeutics..
10.
2022
-
Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy..
10.
2022
-
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma..
10.
2022
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer..
10.
2022
-
Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer..
10.
2022
-
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study..
10.
2022
-
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade..
10.
2022
-
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center..
10.
2022
-
MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer..
10.
2022
-
Immunostimulatory effects of radioimmunotherapy..
10.
2022
-
Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study)..
10.
2022
-
Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses..
10.
2022
-
Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition..
10.
2022
-
Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific antibodies..
10.
2022
-
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival..
9.
2021
-
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study..
9.
2021
-
Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids..
9.
2021
-
Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups..
9.
2021
-
Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy..
9.
2021
-
Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067..
9.
2021
-
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects..
9.
2021
-
Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy..
9.
2021
-
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine..
9.
2021
-
Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study..
9.
2021
-
Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia..
9.
2021
-
Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy..
9.
2021
-
Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors..
9.
2021
-
Fifteen-year follow-up of relapsed indolent non-Hodgkin lymphoma patients vaccinated with tumor-loaded dendritic cells..
9.
2021
-
Metabolic features of cancer cells impact immunosurveillance..
9.
2021
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events..
9.
2021
-
Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release..
9.
2021
-
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia..
9.
2021
-
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer..
9.
2021
-
Obesity diminishes response to PD-1-based immunotherapies in renal cancer..
8.
2020
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events..
8.
2020
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma..
8.
2020
-
Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies..
8.
2020
-
Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey..
8.
2020
-
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy..
8.
2020
-
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer..
8.
2020
-
Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients..
8.
2020
-
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors..
8.
2020
-
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer..
8.
2020
-
M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer..
8.
2020
-
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study..
8.
2020
-
Rationalized inhibition of mixed lineage kinase 3 and CD70 enhances life span and antitumor efficacy of CD8+ T cells..
8.
2020
-
Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung..
8.
2020
-
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy..
8.
2020
-
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing..
8.
2020
-
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial..
8.
2020
-
Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial..
8.
2020
-
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response..
8.
2020
-
Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors..
8.
2020
-
Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce..
8.
2020
-
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors..
8.
2020
-
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study..
8.
2020
-
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer..
8.
2020
-
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma..
8.
2020
-
Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients..
7.
2019
-
The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients..
7.
2019
-
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients..
7.
2019
-
Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program..
7.
2019
-
Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors..
7.
2019
-
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients..
7.
2019
-
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors..
7.
2019
-
Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience..
7.
2019
-
Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients..
6.
2018
-
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis..
6.
2018
-
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden..
6.
2018
-
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial..
6.
2018
-
Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas..
5.
2017
-
Melanoma brain metastases treated with stereotactic radiosurgery and concurrent pembrolizumab display marked regression; efficacy and safety of combined treatment..
5.
2017
-
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia..
4.
2016
-
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma..
4.
2016
-
Current clinical trials testing the combination of immunotherapy with radiotherapy..
4.
2016
-
Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule..
4.
2016
-
Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking?.
4.
2016
-
Route of antigen delivery impacts the immunostimulatory activity of dendritic cell-based vaccines for hepatocellular carcinoma..
3.
2015
-
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma..
3.
2015
-
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation..
3.
2015
-
Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes..
2.
2014
-
Ipilimumab in patients with melanoma and autoimmune disease..
2.
2014
-
Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells..
2.
2014
-
Opportunistic infections in patients treated with immunotherapy for cancer..
2.
2014
-
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma..
1.
2013
-
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma..
1.
2013
-
Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop..
7.
2019
-
Immunogenicity of cell death driven by immune effectors.
2020
-
Immune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial.
2019
-
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
2020
-
The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.
2019
-
Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop.
2018
-
Vaccines for immunoprevention of DNA mismatch repair deficient cancers.
2022
-
Immunological configuration of ovarian carcinoma: features and impact on disease outcome.
2021
-
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
2021
-
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
2021
-
Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer.
2020
-
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity.
2020
-
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
2020
-
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.
2019
-
White paper on microbial anti-cancer therapy and prevention.
2018
-
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
2017
-
Combination immunotherapy: a road map.
2017
-
Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer.
2017
-
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.
2016
-
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.
2014
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)